Frassová Z, Rudá-Kučerová J
Klin Onkol. 2017 Winter;31(1):15-23. doi: 10.14735/amko201815.
Turmeric (Curcuma longa) is mainly known as a constituent of curry spice. The main active ingredient, responsible for most of its biological effects, is the polyphenol curcumin.
This review aims to provide a comprehensive overview of studies evaluating the benefits of therapeutic curcumin use in oncology. Preclinical studies provide information on the mechanism of action and potential toxicity of curcumin. Clinical studies have so far focused mainly on safety, pharmacokinetics, and determination of the optimal dose of curcumin. However, there are a growing number of trials evaluating the anti-tumor and oncopreventive effects of curcumin and its effect in alleviating the adverse effects of chemotherapeutics and radiotherapy. So far, the results have been optimistic and should encourage further research. The main problem associated with curcumin treatment is its low oral bioavailability, which means it must administrated at high doses to be effective. Therefore, curcumin is more appropriate as a local treatment for areas such as the intestine, mucous membrane, or the skin, where there is no need for a strong systemic effect. Curcumin has a good safety profile when used up to several grams. Curcumin can also be used as a food supplement for people at increased risk of oncological disease, such as heavy smokers or those with pre-cancerous lesions. Due to its good safety profile, curcumin can be recommended to oncological patients who request a natural treatment.Key words: phytotherapy - drug-herb interactions - cancer - adverse effects - curcumine - turmeric - Curcuma longaSubmitted: 20. 7. 2017Accepted: 25. 9. 2017 This publication was written at Masaryk University as part of the project "Behavioural psychopharmacology and pharmacokinetics in preclinical drug research", number MUNI/A/1132/2017 with the support of the Specific University Research Grant, as provided by the Ministry of Education, Youth and Sports of the Czech Republic in the year 2018. The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study. The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.
姜黄（Curcuma longa）主要作为咖喱香料的一种成分为人所知。其主要活性成分是多酚类姜黄素，它对姜黄的大部分生物学效应负责。
本综述旨在全面概述评估治疗性使用姜黄素在肿瘤学中的益处的研究。临床前研究提供了关于姜黄素作用机制和潜在毒性的信息。迄今为止，临床研究主要集中在姜黄素的安全性、药代动力学以及最佳剂量的确定。然而，越来越多的试验在评估姜黄素的抗肿瘤和肿瘤预防作用，以及其在减轻化疗和放疗不良反应方面的作用。到目前为止，结果是乐观的，应该鼓励进一步研究。与姜黄素治疗相关的主要问题是其口服生物利用度低，这意味着必须高剂量给药才能有效。因此，姜黄素更适合作为肠道、黏膜或皮肤等部位的局部治疗，这些部位不需要强大的全身效应。姜黄素使用高达几克时具有良好的安全性。姜黄素也可作为肿瘤疾病风险增加人群（如重度吸烟者或有癌前病变者）的食品补充剂。由于其良好的安全性，姜黄素可推荐给寻求自然治疗的肿瘤患者。
植物疗法 - 药物 - 草药相互作用 - 癌症 - 不良反应 - 姜黄素 - 姜黄 - Curcuma longa
2017年7月20日
2017年9月25日
本出版物是在马萨里克大学撰写的，是项目“临床前药物研究中的行为心理药理学和药代动力学”（项目编号MUNI/A/1132/2017）的一部分，得到了捷克共和国教育、青年和体育部2018年提供的特定大学研究资助的支持。作者声明他们在研究中使用的药物、产品或服务方面没有潜在的利益冲突。编辑委员会声明该手稿符合国际医学期刊编辑委员会（ICMJE）对生物医学论文的建议。
